April 17, 2026 a 08:38 am
BMY: Analysts Ratings - Bristol-Myers Squibb Company
The stock of Bristol-Myers Squibb Company (BMY) presents a relatively balanced outlook, with a predominant inclination towards 'Hold' ratings among analysts. The pharmaceutical giant, known for its innovative biopharmaceutical products, faces a cautious market sentiment as reflected by the high number of 'Hold' recommendations. The consistency in 'Buy' ratings alongside a substantial 'Hold' consensus signals a steady yet restrained confidence in the stock's near-term performance.
Historical Stock Grades
The analyst ratings for April 2026 show a predominant 'Hold' sentiment towards BMY with 18 'Hold', 6 'Buy', 4 'Strong Buy', and minimal 'Sell' recommendations.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 6 | |
| Hold | 18 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment towards BMY has shifted significantly over the months. Key trends include:
- The number of 'Strong Buy' ratings decreased from 7 in early 2024 to 4 in 2026, indicating waning confidence.
- 'Hold' recommendations increased, reflecting a cautious stance from analysts.
- Total recommendations have stabilized around a high count of 'Hold', indicating a neutral market sentiment.
Percentage Trends
There has been a notable shift in the distribution of analyst ratings for BMY. Key observations include:
- The percentage of 'Hold' ratings grew from approximately 17% in early 2024 to 72% in 2026, showcasing increased neutrality.
- 'Buy' recommendations have shown stability, while 'Strong Buy' ratings have declined significantly.
- This trend suggests a market climate of caution and decreased bullishness on BMY's potential growth.
Latest Analyst Recommendations
Recent analyst ratings indicate a stable view on BMY. Here's a summary of the latest recommendations:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-09 | Buy | Buy | B of A Securities |
| 2026-04-08 | Neutral | Neutral | Cantor Fitzgerald |
| 2026-04-08 | Buy | Buy | Guggenheim |
| 2026-03-17 | Hold | Hold | HSBC |
| 2026-02-23 | Overweight | Overweight | Piper Sandler |
Analyst Recommendations with Change of Opinion
Some analysts have revised their recommendations, reflecting an evolving market perception:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-07 | Buy | Neutral | UBS |
| 2025-12-15 | Buy | Neutral | B of A Securities |
| 2025-12-12 | Buy | Neutral | Guggenheim |
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-12-16 | Buy | Hold | Jefferies |
Interpretation
The prevailing analyst sentiment reflects a stable but cautious outlook for BMY. While the frequency of 'Hold' ratings indicates a market in contemplation, the absence of significant 'Sell' recommendations suggests that fundamental concerns are limited. However, BMY's market perception reveals uncertainty given the reduction in 'Strong Buy' endorsements. This underscores a market sentiment that is neither emphatic nor pessimistic, suggesting that the company is expected to maintain its current position without substantial gains or losses in valuation.
Conclusion
Bristol-Myers Squibb Company finds itself in a neutral analyst landscape, as mirrored by the prevalent 'Hold' recommendations. The company's broad portfolio across significant pharmaceutical sectors anchors its stability, yet growth perceptions appear tempered, as reflected by reduced 'Strong Buy' ratings. Analysts' sentiment embodies a prudent approach, with limited enthusiasm for immediate growth prospects tempered by solid retention of existing market confidence. Hence, while BMY holds potential defensive merits within portfolios, investors are advised to consider broader market opportunities involving more dynamic forecasts for capital appreciation.